{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:24:11Z","timestamp":1758630251588},"reference-count":28,"publisher":"SLACK, Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n            <jats:p>To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 \u00b5g injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and non-surgical FTMH closure [month 6]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI], 1.1\u20133.7), VMA diameter of 1,500 \u00b5m or less (OR = 4.9; 95% CI, 2.0\u201312.4), phakic lens status (OR = 2.8; 95% CI, 1.5\u20135.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2\u20137.9) predicted VMA resolution. FTMHs with apical diameter of 250 \u00b5m or less were more likely to close than larger holes (58.3% vs. 24.6%;\n              <jats:italic>P<\/jats:italic>\n              = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                . 2016;47:716\u2013723.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20160808-04","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T11:17:08Z","timestamp":1471864628000},"page":"716-723","source":"Crossref","is-referenced-by-count":16,"title":["Baseline Predictors of Vitreomacular Adhesion\/Traction Resolution Following an Intravitreal Injection of Ocriplasmin"],"prefix":"10.3928","volume":"47","author":[{"given":"Timothy L.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniz","family":"Girach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin U.","family":"Dugel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the MIVI-TRUST Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"issue":"2","key":"e_1_3_2_2_2","first-page":"215","article-title":"Perifoveal vitreous detachment is the primary pathogenic event in idiopathic macular hole formation","volume":"119","author":"Johnson MW","year":"2001","unstructured":"Johnson MW, Van Newkirk MR, Meyer KA. Perifoveal vitreous detachment is the primary pathogenic event in idiopathic macular hole formation. Arch Ophthalmol. 2001;119(2):215\u2013222.","journal-title":"Arch Ophthalmol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e328352404c"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.9.1092"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.1.32"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12019"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181eef08c"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)73813-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182a15f8b"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182a6b3e2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110823"},{"volume-title":"Jetrea [package insert]","year":"2014","key":"e_1_3_2_12_2","unstructured":"Jetrea [package insert]. Iselin, NJ: ThromboGenics; May 2014."},{"volume-title":"Jetrea - Summary of Product Characteristics","year":"2013","key":"e_1_3_2_13_2","unstructured":"Jetrea - Summary of Product Characteristics. Leuven, Belgium: ThromboGenics NV; 2013."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0930"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.051"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2185"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.045"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1980.01020030314015"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-004-0934-7"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(82)34610-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080070078039"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3282fc9c4a"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2009.02.016"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.273"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.045"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.091777"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.153189"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20120102-05"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.4.390"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/ophthalmology\/journals\/osli\/2016-8-47-8\/%7Bc09723ff-3699-43c3-80c2-c086ad80548b%7D\/baseline-predictors-of-vitreomacular-adhesiontraction-resolution-following-an-intravitreal-injection-of-ocriplasmin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T02:21:46Z","timestamp":1683080506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20160808-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.3928\/23258160-20160808-04"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20160808-04","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"type":"print","value":"2325-8160"},{"type":"electronic","value":"2325-8179"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}